Clin Pharmacokinet
-
Randomized Controlled Trial
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. ⋯ The pharmacokinetics of tildrakizumab behaves like a typical monoclonal antibody without requiring dosage adjustment.